With rising antibiotic resistance, gonorrhoea is becoming harder to treat. Dr. Sehulong Robert Moraba contributed to the fight against this global threat as a Sub-Investigator in the STI_Zoli001 trial. This was a multi-center, randomized, open-label study to evaluate the efficacy and safety of a single oral dose of Zoliflodacin.
The trial (SAHPRA ref: 20190812) aimed to determine if Zoliflodacin was non-inferior to the standard combination of an injectable cephalosporin and oral azithromycin. Dr. Moraba’s involvement supported the development of the first new antibiotic class for uncomplicated gonorrhoea in over 30 years, offering a crucial new tool for public health.
